Verve Therapeutics (VERV) said Friday the US Food and Drug Administration granted fast track designation for its experimental VERVE-102 treatment for hyperlipidemia and high lifetime cardiovascular risk to lower low-density lipoprotein cholesterol.
The company is testing VERVE-102 in a phase 1b clinical trial. The study's demographic and initial safety and efficacy data are expected in Q2.
Verve Therapeutics shares were up 4.9% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.